The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Dan went on telegram solely to schmooze and get the AGM resolutions over the line,and the money raised was for wages,not some further work on the assets.Its a waiting game for deals.I can’t see the orphan drug route holding sway, if someone is going to sign or buy the assets,they will.They can always apply for that themselves.They have supposedly been in talks a while,so what’s the hold up,they either want them or they don’t,NFX aren’t in a position to play hard ball.
Why wasn’t the Orphan application made earlier,they have been in talks a long time with whoever it is,AZ is my guess,it can’t be that important as the licensee/owner could have applied for it themselves.More a delay tactic by NFX until they can find someone actually interested in taking it.Dan gets a bit too ahead of himself for my liking,I thought it was in the bag the way they were talking.
Randoxgirl what happened to the good news.????
The price in rising in anticipation of Dan Golding and team bringing home a stonking deal,that could blow us out of the water,from where it has been in the doldrums over the last few years.Given the crap we have endured over the last few years,we are lucky the company is still standing,hopefully the phoenix is about to rise from the ashes.GLA
At some point soon the dynamic will change.I don’t think they can be far off news or at least someone knowing something and it trickling into the msrket.Its not Dans preferred route but I hope they sell and get as much as they can for the assets.The results coming so soon after the Christmas break speaks volumes for me,cleans everything up,they have a runway and Maddie and Julian deferring wages,they know what’s coming.
If the results are as good as Pharma we’re expecting then Nuformix could be in the enviable position of having 3 maybe 4 vying for the the license to take NXP002 forward.So either one of them pays a premium for sole rights or could there be possible multiple licenses at play,Boehringer,Glaxo,Sanofi,the mind boggles.And it shouldn’t really take long if one or more of them want first mover advantage.I don’t think we have to wait till September before someone makes a move.
With everything that has gone on over the last few years,they have managed to destroy the company and it’s share price.The only saving grace is Nxp 002 is ready for licensing or a sale,personally I would prefer a sale of the whole company and what it has,rather than wait on another pitiful deal like the Oxilio one.They don’t have much money left so I am sure the need for either is paramount,because a raise from these levels is going to hurt everyone.
Mariola has been in the job 9 months,Their forte is testing for diseases,they have had an opportunity dropped in their lap,not one mention of Covid from them.The one test they have a hand in,stroke,has been put on the back burner by Randox,why,because Randox concentrated on Covid,where there was money to be made.Then what do they do,”reward” board members with share options @1p,why not 5p,still a nice turnover,1p is an absolute pssstake,and 15% of the companies issue,Let’s just hope there is something in the background that justifies these rewards,but usually with PRM,there won’t be.
Another kick in the teeth for long term holders,why at 1p,not a great reflection on future price.And what has Mariola done so far to warrant such a reward.??
Here is an opportunity for PRM.New strains of COVID,develop a test that can differentiate between the various strains so that each can be treated accordingly with the relevant vaccine,testing is supposedly their forte.No doubt they will look on while someone else does it and then publish a thesis in some obscure journal on what could have been if they had moved quicker.
Given the appalling attitude of PRM to the average PI,I would say Diggle wishes he had never bought 1 share,let alone the millions he does own,an absolute shambles of a company.